Triptorelin extended release - Foresee Pharmaceuticals
Alternative Names: FP-014Latest Information Update: 10 Dec 2024
Price :
$50 *
At a glance
- Originator Foresee Pharmaceuticals
- Class Antineoplastics; Antivirals; Hormones; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
- Mechanism of Action Gonadotropin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Prostate cancer
Most Recent Events
- 10 Dec 2024 Phase-II clinical trials in Prostate cancer (SC), before December 2024 (Foresee Pharmaceuticals pipeline, December 2024)
- 10 Dec 2024 Foresee Pharmaceuticals plans phase III trials for Prostate cancer (Late-stage disease) (Foresee Pharmaceuticals pipeline, December 2024)
- 10 Oct 2023 Preclinical trials in Prostate cancer in USA (SC) (Foresee Pharmaceuticals pipeline; October 2023)